ArticleBone marrow transplantation2012
Reduced-intensity conditioning hematopoietic SCT for pediatric patients with LAD-1: clinical efficacy and importance of chimerism.
Article in Bone marrow transplantation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study.Bone marrow transplantation · 2016Trial
- Allogeneic hematopoietic stem cell transplantation with the modified myeloablative conditioning regimen for children with chronic active Epstein-Barr virus infection.Pediatric investigation · 2022Article
- Haploidentical hematopoietic stem cell transplantation for pediatric patients with chronic active Epstein-Barr virus infection: a retrospective analysis of a single center.World journal of pediatrics : WJP · 2021Article
- Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III.Blood advances · 2021Article
- Case Report: A Case of Leukocyte Adhesion Deficiency, Type III Presenting With Impaired Platelet Function, Lymphocytosis and Granulocytosis.Frontiers in pediatrics · 2021Article
- Haploidentical Hematopoietic Stem Cell Transplantation for XIAP Deficiency: a Single-Center Report.Journal of clinical immunology · 2020Article
- Successful umbilical cord blood transplantation in children with leukocyte adhesion deficiency type I.Translational pediatrics · 2020Article
- Successful reconstitution of leukocyte adhesion defect after umbilical cord blood stem cell transplant.Central-European journal of immunology · 2020Article
- A Stable Mixed Chimera After SCT with RIC in an Infant with IκBα Hypermorphic Mutation.Journal of clinical immunology · 2017Article
- Hematopoietic Stem Cell Transplantation for XIAP Deficiency in Japan.Journal of clinical immunology · 2017Article
- Lentiviral Vector-Mediated Correction of a Mouse Model of Leukocyte Adhesion Deficiency Type I.Human gene therapy · 2016Article
- Leucocyte adhesion deficiency type 1 with developmental delay secondary to CMV infection and filiation questions.BMJ case reports · 2015Article
- Hematopoietic SCT in Iranian children 1991-2012.Bone marrow transplantation · 2015Article
- Remission of Crohn's disease after cord blood transplantation for leukocyte adhesion deficiency type 1.Bone marrow transplantation · 2013Article
- Successful allogeneic stem cell transplantation with a reduced-intensity conditioning in a case of leukocyte adhesion deficiency type III.Hematology, transfusion and cell therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric patients with leukocyte adhesion deficiency type-I (LAD-I) experience severe and recurrent life-threatening bacterial infections with failure of pus formation and delayed wound healing. LAD-I is a rare inherited disease caused by mutation in the leukocyte CD18 integrin expression, resulting in defective adherence and migration of leukocytes, in particular neutrophilic granulocytes through the intravascular space. Hematopoietic SCT is the only curative treatment option available to patients with LAD-I. Since 2007, in a prospective trial, reduced-intensity conditioning regimen have been developed for 10 consecutive patients with LAD-I who were referred to our center. Based upon available data, it is the first time that such a number of patients affected by LAD-I have been treated with this regimen. This study attempts to show that reduced-intensity regimen leads to a favorable result in LAD-I patients even in those who have experienced comorbid complications. Following transplantation, some patients develop mixed chimerism, however, in our study mixed chimerism was not followed by transplant rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.